By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Moving fast in the respiratory space to advance a potential first-time therapy.
Kinaset Therapeutics is developing its single asset, an inhaled pan-JAK (Janus kinase signal transducer) inhibitor, initially for severe asthma and other respiratory diseases such as chronic obstructive pulmonary disease (COPD). Coded KN-002, the acquired pipeline product has entered a U.K.-based Phase 1b trial to assess safety and optimum dosing in patients with asthma treated with standard-of-care and patients with COPD receiving standard-of-care inhaled medicines. Further in-licensing may also expand the pipeline.